Kalytera Identifies Sites for Planned GvHD Clinical Trials …

VANCOUVER, British Columbia, April 25, 2017 (GLOBE NEWSWIRE) — Kalytera Therapeutics, Inc. (KALY.V), a clinical-stage biopharmaceutical company developing next-generation cannabinoid-derived therapeutics, today announced that it has developed the multi-center location component of the plan for the proposed clinical trials to evaluate cannabidiol (“CBD”) for the prevention and treatment of Graft versus Host Disease (“GvHD”). Kalytera is developing this clinical trial plan with the intent of obtaining FDA and EMEA approval for commercialization.

Kalytera expects to finalize and publish the details of its clinical trial plan during the current quarter ending June 30, 2017. The plan will include the clinical trial designs, the anticipated timelines for initiation and completion, as well as the principal endpoints. The trials are intended to build on the encouraging data seen in the recently completed ... read more at: http://finance.yahoo.com/news/kalytera-identifies-sites-planned-gvhd-123000760.html